Rhaeos

Rhaeos, Inc. is a clinical-stage medical device company focused on developing wearable sensors to improve the care of people suffering from chronic and difficult-to-treat conditions. The company's flagship product, FlowSense, is a patented, non-invasive, wireless thermal sensor designed to address a critical unmet need in managing hydrocephalus, a neurological condition characterized by an abnormal accumulation of cerebrospinal fluid (CSF) in the brain's ventricles.

FlowSense is a bandage-sized patch that adheres to the skin above the implanted shunt tubing and rapidly monitors CSF flow through the shunt system. It wirelessly transmits critical data on shunt functionality to a mobile app within minutes, supporting clinical decision-making and treatment plans optimization. Approximately 50% of neurosurgically implanted ventricular shunts, the standard treatment for hydrocephalus, fail within the first two years, often leading to emergency room visits and repeat surgeries.

In 2020, the US Food and Drug Administration granted FlowSense the Breakthrough Device Designation, enabling Rhaeos to work closely with the agency to streamline the market clearance process. Following a successful USD 10.5 million Series A funding round led by the Steele Foundation for Hope in February 2023, the company anticipates making FlowSense commercially available to physicians and patients in 2023. It is currently being evaluated in an FDA pivotal study across multiple centers in the US

Rhaeos' innovative technology originated from over a decade of research in epidermal electronics and thermal flow sensing conducted by co-founders John A. Rogers, Ph.D., and Siddharth Krishnan, Ph.D., at Northwestern University. The company has raised over USD 18 million to date through equity investments, grants from entities like the National Institutes of Health, and non-dilutive funding sources.